IRLAB Therapeutics AB Class A (6IRA) Price & Analysis

Compare

1 Followers

6IRA Stock Chart & Stats

€0.18

-€0.01(-1.25%)

At close: Jan 08 4:00 PM EST

€0.18

-€0.01(-1.25%)

Day’s Range― - ―

52-Week Range€0.14 - €0.80

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€12.46M

Enterprise Value€82.17M

Total Cash (Recent Filing)€81.86M

Total Debt (Recent Filing)€29.95M

Price to Earnings (P/E)―

Beta-0.08

Next Earnings

May 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding84,858,246

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio-0.48

Price to Book (P/B)4.30

Price to Sales (P/S)2.30

P/FCF Ratio-2.39

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.25

Revenue Forecast (FY)€10.19M

Bulls Say, Bears Say

Bulls Say

Focused CNS R&D PipelineA clear strategic focus on CNS and small‑molecule drug discovery creates a durable competitive angle: concentrated scientific expertise, targeted resource allocation, and clearer partnership value propositions to biopharma collaborators and specialty investors over a multi‑quarter horizon.

Improving Leverage; Not Currently DistressedMeasured deleveraging—debt roughly in line with equity and improved leverage versus 2024—strengthens financial flexibility and lowers near‑term solvency risk. That structural improvement expands options for partnerships or financing across the next several quarters.

Reduced Cash Burn TrendAlthough still cash‑negative, an improving burn rate reflects tighter expense control or sequencing of R&D spend and extends runway. Sustained lower burn is a durable operational improvement that increases likelihood management can advance trials without immediate dilutive financing.

Bears Say

Persistent Multi‑year Losses And Negative MarginsMulti‑year negative margins indicate the core development model is not covering costs and will keep the company dependent on external capital until a commercial product or material licensing milestone occurs. Sustained losses erode equity and constrain strategic optionality.

Negative Cash Generation; Reliance On External FundingPersistent negative operating and free cash flow means ongoing dependence on partner payments, milestones, or capital markets. That structural funding requirement raises execution risk and could force dilutive financing or program prioritization over the next several quarters.

Revenue Volatility And Lack Of Commercial ProductsHighly variable revenue and no material commercial sales create unstable cash inflows tied to timing of partnerships or milestones. This structural volatility hampers predictable funding and long‑term planning until a product reaches commercialization.

IRLAB Therapeutics AB Class A News

IRLAB to Showcase Parkinson’s Pipeline at Gothenburg Life Science Day

An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB, a...

11d ago

IRLAB Triggers USD 3 Million Milestone as First Patient Dosed in IRL757 Parkinson’s Apathy Trial

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement. IRLAB Therapeutics has dosed the first...

15d ago

IRLAB Advances CNS Pipeline as 2025 Loss Widens and Cash Position Strengthens

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement. IRLAB Therapeutics reported full-year 2025 results...

16d ago

IRLAB Wins Expert Backing to Advance Parkinson’s Drug Pirepemat After Positive Phase IIb Signals

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics has received...

21d ago

IRLAB to Webcast Year-End 2025 Results as Parkinson’s Pipeline Advances

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB, a...

23d ago

IRLAB partners with Denmark’s Biomia to apply AI-driven ISP platform to CNS drug candidates

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics has entered...

2M ago

IRLAB Wins Green Light for Phase Ib Trial of Novel Apathy Drug in Parkinson’s

IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has provided an announcement. IRLAB Therapeutics has obtained regulatory and...

3M ago

IRLAB Secures New Patent for Mesdopetam, Strengthening Market Position

The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ). IRLAB Therapeutics AB announced...

3M ago

IRLAB to Present at Redeye Technology & Life Science Day 2025

An announcement from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB announced...

4M ago

IRLAB Therapeutics Appoints Nomination Committee for 2026 AGM

An update from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) is now available. IRLAB Therapeutics AB has...

4M ago

6IRA FAQ

What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?

IRLAB Therapeutics AB Class A lowest stock price was €0.14 and its highest was €0.80 in the past 12 months.

What is IRLAB Therapeutics AB Class A’s market cap?

IRLAB Therapeutics AB Class A’s market cap is €12.46M.

When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?

IRLAB Therapeutics AB Class A’s upcoming earnings report date is May 06, 2026 which is in 54 days.

How were IRLAB Therapeutics AB Class A’s earnings last quarter?

IRLAB Therapeutics AB Class A released its earnings results on Feb 25, 2026. The company reported -€0.027 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.027.

Is IRLAB Therapeutics AB Class A overvalued?

According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does IRLAB Therapeutics AB Class A pay dividends?

IRLAB Therapeutics AB Class A does not currently pay dividends.

What is IRLAB Therapeutics AB Class A’s EPS estimate?

IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does IRLAB Therapeutics AB Class A have?

IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.

What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?

IRLAB Therapeutics AB Class A reported an EPS of -€0.027 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.051%.

Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?

Currently, no hedge funds are holding shares in DE:6IRA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

IRLAB Therapeutics AB Class A

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.